SOURCE: Synergetics

Synergetics

October 01, 2012 06:30 ET

Synergetics Reports Record Quarterly Sales and Fourth Quarter and Fiscal 2012 Results

O'FALLON, MO--(Marketwire - Oct 1, 2012) - Synergetics USA, Inc. (NASDAQ: SURG) ("Synergetics" or the "Company"), a medical device company that designs, manufactures, and markets innovative surgical devices for ophthalmic and neurosurgical applications, today announced results for the fourth quarter and year ended July 31, 2012. 

Fourth Quarter Summary:

  • Total sales were $16.9 million, a year-over-year increase of 7.7% and a 15.7% sequential increase over third quarter of fiscal 2012.
  • OEM sales increased 26.8% and Ophthalmic sales declined 3.9% year-over-year.
  • Domestic sales increased 12.1% and International sales declined 3.0% year-over-year.
  • Disposable products sales increased 8.8% and capital equipment sales increased 1.6%.
  • GAAP EPS was $0.08 versus $0.08 for the comparable period last year.
  • Cash flow from operations was $547,000.

Fiscal Year Summary:

  • Total sales were $60.0 million, up 7.8% year-over-year.
  • OEM sales increased 23.2% and Ophthalmic sales increased 2.0% year-over-year.
  • Domestic sales increased 12.9% and International sales declined 4.2% year-over-year.
  • GAAP EPS from continuing operations* was $0.24 versus $0.23 in fiscal year 2011.

"Our fourth quarter of fiscal year 2012 concluded with solid 7.7% top line growth driven by momentum in our OEM business due to robust demand from our marketing partners. Our base Ophthalmic business decelerated in the fourth quarter. However, we recorded strong performance in the emerging markets of Brazil, Russia and India, as well as continued account penetration in the U.S. with VersaPACK™, trends that bode well for Synergetics' long-term growth prospects. Moreover, we are optimistic that the recent regulatory approval of VersaVIT™, our innovative, portable vitrectomy machine, will benefit Ophthalmic sales, particularly in the latter half of fiscal 2013. We are excited to be showcasing VersaVIT™ at the American Academy of Ophthalmology (AAO) meeting in Chicago beginning November 10th," said David M. Hable, the Company's President and Chief Executive Officer.

Mr. Hable continued, "Importantly, although we still anticipate challenges related to the global macroeconomic environment, our backlog entering the new fiscal year is quite strong and the progress we have made on our lean initiatives this year provides a solid foundation on which to build an increasingly efficient and increasingly profitable organization in the future. Thus, we anticipate improving financial performance in fiscal year 2013, both in terms of revenue and EPS growth, despite our planned investments to drive our new product introductions and the incremental expenses related to the medical device tax this year."

Fourth Quarter Results

Fourth quarter of fiscal 2012 sales totaled $16.9 million, an increase of 7.7% compared to sales of $15.7 million in the fourth quarter of fiscal 2011 and an increase of 15.7% compared to sales of $14.6 million in the third quarter of fiscal 2012. Fourth quarter sales performance was led by a 26.8% improvement in OEM sales through our marketing partners partially offset by a 3.9% decline in Ophthalmic sales. OEM sales in the quarter include the recognition of $321,000 of deferred revenues compared to $443,000 in the prior year fourth quarter.

*GAAP net income was $0.22 versus $0.23 in fiscal year 2011

  • Domestic sales improved 12.1% to $12.5 million in the fourth quarter from the prior year's fourth quarter due to the strength in OEM sales. International sales of $4.4 million declined 3.0% year-over-year, primarily due to weakness in the European market. Strong orders from the emerging markets of Brazil, Russia and India offset weakness in other international markets which faced continued economic challenges and competitive factors again this quarter.

  • Ophthalmic sales declined 3.9% to $9.2 million compared with $9.5 million the fourth quarter of fiscal 2011. Domestic Ophthalmic sales declined 4.8% and International Ophthalmic sales declined 2.9% year-over-year. Growth in disposable ophthalmic products was more than offset by weak demand for capital equipment given a more cautious capital spending environment. Within our disposable business, while we continue to make inroads with our VersaPACK™ kits in the U.S., the evaluation process remains lengthy, and some of our older, legacy products are encountering slower market growth globally. 

  • Total OEM sales increased 26.8% to $7.5 million compared with $5.9 million in the fourth quarter of fiscal 2011. OEM sales, which include sales to our marketing partners, benefited primarily from the shipment of a large order to Mobius Therapeutics, LLC as well as heightened demand for disposable products and generators from Stryker Corporation ("Stryker") and Codman & Shurtleff, Inc. ("Codman"), respectively, this quarter. We successfully resolved the production-related backlog that adversely affected OEM sales during the third quarter, and with continued robust demand, we expect strong sales to Stryker and Codman to continue into fiscal 2013.

  • Disposable product sales totaled $13.8 million, an increase of 8.8% compared with sales of $12.6 million last year. Disposables growth was driven by stronger demand from our OEM partners and our continued account penetration for our VersaPACK™ product kits in the 2012 period. Capital equipment sales totaled $2.8 million in the fourth quarter of fiscal 2012 compared with $2.7 million in the fourth quarter of fiscal 2011, a 1.6% increase year-over-year due to the aforementioned constraints on capital spending. On a sequential basis, capital equipment sales growth improved 29.5% versus the third quarter, as the Company successfully worked through the backlog of orders.

Gross profit for the fourth quarter of fiscal 2012 totaled $9.8 million, or 58.2% of sales, compared with $9.4 million, or 60.2% of sales, in the fourth quarter of fiscal 2011. The margin performance, while up 450 basis points sequentially, was down 200 basis points from the prior year due to a mix shift in revenues in 2012 to our OEM business which experienced a strong 26.8% increase in sales. However, these OEM sales are below the Company's average gross profit margin.

Total operating expenses increased to $6.9 million, or 40.7% of sales, in the fourth quarter from $6.5 million, or 41.3% of sales, in the comparable period largely due to additional stock compensation included in general and administrative expenses. Operating income for the fourth quarter of fiscal 2012 of $2.9 million was essentially flat compared with $3.0 million last year.

Income from continuing operations was $1.9 million, or $0.08 per diluted share, as compared to $2.0 million, or $0.08 per diluted share, for the same period of fiscal 2011. Earnings before interest, taxes, depreciation and amortization ("EBITDA") totaled $3.3 million in the fourth quarter of fiscal 2012 as compared to EBITDA of $3.4 million in the prior year fourth quarter. 

Fiscal Year Results

Total sales for fiscal 2012 increased 7.8% to $60.0 million compared with $55.7 million in fiscal year 2011. Income from continuing operations for fiscal 2012 increased 5.3% to $6.0 million, or $0.24 per diluted share, versus $5.7 million, or $0.23 per diluted share, in fiscal 2011. In addition, there was a net of loss from discontinued operations of $0.4 million or $0.02 per diluted share, related to the completion of the sale of assets from our plastic injection molding business in the fiscal 2012 period. Net income for fiscal year 2012 including discontinued operations was $5.6 million, or $0.22 per diluted share, remaining essentially flat compared with $5.6 million, or $0.23 per diluted share, in fiscal 2011. 

As of July 31, 2012, the Company had approximately $12.7 million in cash on its balance sheet and no debt compared with $18.4 million in cash and $1.1 million in debt at the end of fiscal 2011. The reduction in cash over this period was primarily due to a tax payment of $5.8 million related to the Alcon, Inc. supply agreement.

Conference Call Information

Synergetics USA, Inc. will host a conference call today at 9:30 a.m. Central Time (10:30 a.m. Eastern) to discuss fourth quarter and fiscal year 2012 results and other recent developments, and to review its growth strategy. The toll free dial-in number to participate live on this call is (800) 588-4973, confirmation code 33288783. For callers outside the U.S., the number is (847) 230-5643. The conference call will also be available live via webcast on the investor relations section of the Company's website www.synergeticsusa.com. A replay will be available on the Company's website for approximately 30 days.

About Synergetics USA, Inc.

Through continuous improvement and development of our people, our mission is to design, manufacture and market innovative surgical devices, surgical equipment and consumables of the highest quality in order to assist and enable surgeons who perform surgery around the world to provide a better quality of life for their patients. 

Synergetics USA, Inc. is a leading supplier of precision surgical devices. The Company's primary focus is on the disciplines of ophthalmology and neurosurgery. Our distribution channels include a combination of direct and independent distributor sales organizations and important strategic alliances with market leaders. The Company's product lines focus upon precision engineered, disposable and reusable devices, surgical equipment, procedural kits and the delivery of various energy modalities for the performance of surgery including: (i) laser energy, (ii) ultrasonic energy, (iii) radio frequency energy for electrosurgery and lesion generation and (iv) visible light energy for illumination, and where applicable, simultaneous infusion (irrigation) of fluids into the operative field. The Company's website address is http://www.synergeticsusa.com.

Use of Non-GAAP Financial Information

In addition to results reported in accordance with GAAP, the Company occasionally provides non-GAAP financial information that management uses in evaluating the Company's performance, such as EBITDA. These non-GAAP amounts, including EBITDA, consist of GAAP amounts excluding inventory write-down and disposition charges to the extent occurring during the period. EBITDA is defined as income from continuing operations before interest expense, income taxes, depreciation and amortization.

The Company measures its performance primarily through its operating profit. In addition to its consolidated financial statements presented in accordance with GAAP, management uses certain non-GAAP measures, including EBITDA, to measure our operating performance. 

EBITDA is presented to enhance an understanding of the Company's operating results and is not intended to represent cash flow or results of operations. The use of EBITDA provides an indication of the Company's ability to service debt and measure operating performance. Management believes EBITDA is useful in evaluating the Company's operating performance compared to other companies in its industry and is beneficial to investors, potential investors and other key stakeholders, including creditors, who use this measure in their evaluation of the Company's performance.

EBITDA does have certain material limitations primarily due to the exclusion of certain amounts that are material to the Company's results of operations, such as interest expense, income tax expense, depreciation and amortization. Due to these limitations, EBITDA should not be considered a measure of discretionary cash available to the Company to invest in its business and should be utilized in conjunction with other information contained in the Company's unaudited consolidated financial statements prepared in accordance with GAAP.

Forward-Looking Statements

Some statements in this release may be "forward-looking statements" for the purposes of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the year ended July 31, 2011, as updated from time to time in our filings with the Securities and Exchange Commission. The Company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.

 
Synergetics USA, Inc. and Subsidiaries
Consolidated Balance Sheets
July 31, 2012 and 2011
(Dollars in thousands, except share and per share data)
           
    2012     2011
Assets   (Unaudited)      
Current assets              
  Cash and cash equivalents   $ 12,680     $ 18,399
  Accounts receivable, net of allowance for doubtful accounts of $319 and $282, respectively     11,795       11,148
  Inventories     15,679       12,082
  Prepaid expenses     825       961
  Deferred income taxes     1,247       792
  Assets held for sale     --       868
    Total current assets     42,226       44,250
Property and equipment, net     9,239       8,561
Intangible and other assets              
  Goodwill     10,660       10,660
  Other intangible assets, net     11,278       11,792
  Deferred income taxes     4,088       4,915
  Patents, net     1,179       1,050
  Cash value of life insurance     93       82
    Total assets   $ 78,763     $ 81,310
Liabilities and stockholders' equity              
Current liabilities              
  Current maturities of long-term debt   $ --     $ 1,053
  Accounts payable     2,144       1,567
  Accrued expenses     2,844       3,193
  Income taxes payable     191       6,233
  Deferred revenue     1,288       540
    Total current liabilities     6,467       12,586
Long-term liabilities              
  Deferred revenue     15,818       18,060
    Total long-term liabilities     15,818       18,060
    Total liabilities     22,285       30,646
Commitments and contingencies              
Stockholders' equity              
  Common stock at July 31, 2012 and July 31, 2011, $0.001 par value, 50,000,000 shares authorized; 25,160,069 and 24,970,884 shares issued and outstanding, respectively     25       25
  Additional paid-in capital     26,421       25,598
  Retained earnings     30,538       24,952
  Accumulated other comprehensive income (loss):              
  Foreign currency translation adjustment     (506 )     89
    Total stockholders' equity     56,478       50,664
    Total liabilities and stockholders' equity   $ 78,763     $ 81,310
               
               
               
Synergetics USA, Inc. and Subsidiaries  
Unaudited, Consolidated Statements of Income  
Fiscal Quarters Ended July 31, 2012 and 2011  
(Dollars in thousands, except share and per share data)  
             
    2012     2011  
Net sales   $ 16,861     $ 15,652  
Cost of sales     7,052       6,224  
    Gross profit     9,809       9,428  
Operating expenses                
  Research and development     1,009       1,126  
  Sales and marketing     3,030       2,945  
  General and administrative     2,824       2,391  
      6,863       6,462  
    Operating income     2,946       2,966  
Other income (expenses)                
  Investment income     8       17  
  Interest expense     --       (20 )
  Miscellaneous     (4 )     --  
      4       (3 )
    Income from continuing operations before provision for income taxes     2,950       2,963  
Provision for income taxes     1,008       922  
    Income from continuing operations   $ 1,942     $ 2,041  
Loss from discontinued operations, net of income tax benefit of $5 and $2, respectively     --       4  
    Net income   $ 1,942     $ 2,037  
Earnings per share:                
  Basic                
    Income from continuing operations   $ 0.08     $ 0.08  
    Loss from discontinued operations     0.00       0.00  
    Net income   $ 0.08     $ 0.08  
  Diluted                
    Income from continuing operations   $ 0.08     $ 0.08  
    Loss from discontinued operations     0.00       0.00  
    Net income   $ 0.08     $ 0.08  
  Basic weighted average common shares outstanding     25,165,493       24,970,271  
  Diluted weighted average common shares outstanding     25,293,168       25,137,786  
                 
                 
                 
Synergetics USA, Inc. and Subsidiaries  
Consolidated Statements of Income  
Years Ended July 31, 2012, 2011 and 2010  
(Dollars in thousands, except share and per share data)  
                   
    2012     2011     2010  
    (Unaudited)              
Net sales   $ 60,014     $ 55,657     $ 52,010  
Cost of sales     25,495       22,876       22,050  
    Gross profit     34,519       32,781       29,960  
Operating expenses                        
  Research and development     3,642       3,713       3,008  
  Sales and marketing     11,881       11,474       11,958  
  General and administrative     10,515       9,245       8,903  
      26,038       24,432       23,869  
    Operating income     8,481       8,349       6,091  
Other income (expenses)                        
  Investment income     40       99       38  
  Interest expense     (43 )     (202 )     (491 )
  Settlement gain     --       --       2,398  
  Gain (loss) on sale of product line     --       (99 )     817  
  Miscellaneous     (11 )     (11 )     23  
      (14 )     (213 )     2,785  
    Income from continuing operations before provision for income taxes     8,467       8,136       8,876  
Provision for income taxes     2,499       2,467       3,109  
    Income from continuing operations   $ 5,968     $ 5,669     $ 5,767  
Loss from discontinued operations, net of income tax benefit of $193, $24 and $17, respectively     382       36       34  
    Net income   $ 5,586     $ 5,633     $ 5,733  
Earnings per share:                        
  Basic                        
    Income from continuing operations   $ 0.24     $ 0.23     $ 0.23  
    Loss from discontinued operations     (0.02 )     0.00       0.00  
    Net income   $ 0.22     $ 0.23     $ 0.23  
  Diluted                        
    Income from continuing operations   $ 0.24     $ 0.23     $ 0.23  
    Loss from discontinued operations     (0.02 )     0.00       0.00  
    Net income   $ 0.22     $ 0.23     $ 0.23  
  Basic weighted average common shares outstanding     25,100,064       24,901,832       24,618,403  
  Diluted weighted average common shares outstanding     25,253,580       25,035,095       24,672,605  
                         
                         
                         
Synergetics USA, Inc. and Subsidiaries
Unaudited Table of Net Income and EBITDA
Three Months and Years Ended July 31, 2012 and July 31, 2011
(Dollars in thousands)
             
EBITDA Reconciliation            
             
    Three Months Ended   Fiscal Year Ended
    July 31, 2012   July 31, 2011   July 31, 2012   July 31, 2011
GAAP net income from continuing operations   $ 1,942   $ 2,047   $ 5,968   $ 5,669
Interest expense     --     20     43     202
Income taxes     1,008     922     2,499     2,467
Depreciation     198     233     1,093     972
Amortization     116     163     601     653
EBITDA   $ 3,264   $ 3,385   $ 10,204   $ 9,963
                         
                         
                         
Synergetics USA, Inc. and Subsidiaries  
Consolidated Statements of Cash Flows  
Years Ended July 31, 2012, 2011 and 2010  
(Dollars in thousands, except share and per share data)  
                   
    2012     2011     2010  
Cash Flows from operating activities   (Unaudited)              
  Net income   $ 5,586     $ 5,633     $ 5,733  
  Plus: Loss from discontinued operations - net of tax     382       36       34  
  Income from continuing operations     5,968       5,669       5,767  
  Adjustments to reconcile net income to net cash provided by operating activities                        
    Depreciation     1,093       972       986  
    Amortization     601       653       879  
    Provision for doubtful accounts receivable     50       (9 )     (48 )
    Stock-based compensation     764       358       287  
    Deferred income taxes     153       (6,388 )     (588 )
    Loss (gain) on sale of equipment     --       50       (16 )
    Loss (gain) on sale of product line     --       99       (817 )
Changes in assets and liabilities                        
  (Increases) decreases in:                        
    Accounts receivable     (844 )     (2,095 )     (303 )
    Inventories     (3,695 )     (291 )     3,138  
    Prepaid expenses     93       (150 )     (389 )
    Income taxes refundable     219       --       --  
  (Decrease) increase in:                        
    Accounts payable     615       (253 )     (112 )
    Accrued expenses     (183 )     427       (453 )
    Deferred revenue     (1,494 )     (430 )     19,030  
    Income taxes payable     (5,848 )     6,243       (9 )
      Net cash (used in) provided by operating activities     (2,508 )     4,855       27,352  
Net cash provided by (used in) discontinued operations     59       (68 )     (43 )
Net cash (used in) provided by operating activities     (2,449 )     4,787       27,309  
Cash Flows from investing activities                        
    Proceeds on the sale of equipment     --       11       16  
    Purchase of property and equipment     (1,809 )     (1,687 )     (892 )
    Acquisition of patents and other intangibles     (214 )     (273 )     (64 )
    Proceeds from the sale of product line     --       --       1,527  
    Increase in cash value of life insurance     (11 )     (10 )     (9 )
      Net cash (used in) provided by continuing investing activities     (2,034 )     (1,959 )     578  
Net cash used in discontinued operations     --       (382 )     (241 )
Net cash (used in) provided by investing activities     (2,034 )     (2,341 )     337  
Cash flows from financing activities                        
    Excess of outstanding checks over bank balance     --       --       (75 )
    Net repayments on lines-of-credit     --       --       (5,035 )
    Principal payments on revenue bonds payable     --       (1,728 )     (1,935 )
    Payment on debt incurred for acquisition of trademark     (313 )     (598 )     (564 )
    Principal payments on long-term debt     (740 )     (685 )     (1,620 )
    Tax benefit associated with the exercise of non-qualified stock options     24       125       31  
    Proceeds from the issuance of common stock     35       210       68  
      Net cash used in financing activities     (994 )     (2,676 )     (9,130 )
Foreign exchange rate effect on cash and cash equivalents     (242 )     (40 )     (7 )
Net (decrease) increase in cash and cash equivalents     (5,719 )     (270 )     18,509  
Cash and cash equivalents                        
    Beginning     18,399       18,669       160  
    Ending   $ 12,680     $ 18,399     $ 18,669  
                         

Contact Information

  • SYNERGETICS USA, INC.
    3845 Corporate Centre Drive
    O'Fallon, Missouri 63368
    (636) 939-5100
    http://www.synergeticsusa.com
    Pamela G. Boone
    Chief Financial Officer